Antiblastic drug targeting to hepatocellular carcinoma cells: a potential therapeutic improvement?
Service d'Hépatogastro, Hôtel Dieu Hospital, Lyon, France.
P
P
Merle
C
C
Trepo
D000606:Amino Sugars / Q000008:administration & dosage; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004337:Drug Carriers; D018432:Drug Resistance, Multiple; D005467:Floxuridine / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D011107:Polylysine / Q000008:administration & dosage*
D000606:Amino Sugars; D000964:Antimetabolites, Antineoplastic; D004337:Drug Carriers; D005467:Floxuridine; C032233:lactosamine; D011107:Polylysine